Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer

New England Journal of Medicine

Volumn 342, Issue 15, 2000, Pages 1069-1076

  Stadtmauer, Edward A ^a   O'Neill, Anne ^b   Goldstein, Lori J ^c   Crilley, Pamela A ^d   Mangan, Kenneth F ^e   Ingle, James N ^f   Brodsky, Isadore ^d   Martino, Silvana ^g   Lazarus, Hillard M ^h   Erban, John K ⁱ   Sickles, Cheryl ^a   Glick, John H ^a   Luger, Selina M ^a   Klumpp, Thomas R ^e   Litzow, Mark R ^f   Topolsky, David L ^j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e TEMPLE UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

^g JOHN WAYNE CANCER INSTITUTE   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

^j HAHNEMANN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; SURVIVAL RATE; THIOTEPA;

EID: 0034643512     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200004133421501     Document Type: Article

References (19)

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
2. Peters WP, Shpall EJ, Jones RB, et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988;6:1368-76.
3. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989;7:1824-30.
4. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991;83:920-6.
5. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992;10:102-10.
6. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992;10:1743-7.
7. Antman KH, Rowlings PA, Vaughan WP, et al. High dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15:1870-9.
8. Distribution and frequencies of autotransplants performed between 1992 and 1997 and registered with the ABMTR. Vol. 5. ABMTR Newsletter. December 1998:5. (Milwaukee: IBMTR/ABMTR Statistical Center.)
9. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970;36:507-15.
10. Eder JP, Elias A, Shea TC, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990;8:1239-45.
11. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
12. Jennison C, Turnbull BW. Interim analyses: the repeated confidence interval approach. J R Stat Soc [B] 1989;51:305-61.
13. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-56.
14. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997;15: 3171-7.
15. Garcia-Carbonero R, Hidalgo M, Paz-Artes L, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997;15:3178-84.
16. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996;14:66-9.
17. Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04. Proc Am Soc Clin Oncol 1999;18:43a. abstract.
18. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
19. Researcher under investigation. Press release of the University of the Witwatersrand Medical School, Johannesburg, South Africa, February 3, 2000. (See http://www.wits.ac.za/depts/wcs/media/index.htm.)